• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大规模生产关于 COVID-19 的系统评价:PROSPERO 记录分析。

The mass production of systematic reviews about COVID-19: An analysis of PROSPERO records.

机构信息

Graduate Program in Dentistry, Meriodional College/IMED, Passo Fundo, Brazil.

Graduate Program in Dentistry, Federal University of Pelotas (UFPEL), Pelotas, RS, Brazil.

出版信息

J Evid Based Med. 2021 Feb;14(1):56-64. doi: 10.1111/jebm.12426. Epub 2021 Feb 17.

DOI:10.1111/jebm.12426
PMID:33595200
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8013525/
Abstract

OBJECTIVE

This study aimed to assess the characteristics of different designs of systematic reviews (SRs) registered in the International Prospective Register of Systematic Reviews (PROSPERO) about COVID-19.

METHODS

The search was performed in the PROSPERO database using the strategy proposed by the database and considered only human studies. The last date of the search was April 27, 2020. Full text of all records was accessed, and data were extracted by a single researcher, which was further double-checked by another researcher. A descriptive analysis was performed considering record characteristics using tables.

RESULTS

We included 564 records from which the vast majority were registered as SRs (n = 513, 91%). In general, we found poor reporting and missing or confusing information, since 84% of the records (n = 474) did not report the full search that would be adopted, 16% (n = 90) did not report clearly the databases that would be used, and 49.1% (n = 277) did not report the number of primary outcomes. The main focus of most of the records involved clinical, epidemiological, complication, and laboratory characteristics (n = 173, 30.7%) or the treatment of COVID-19 (n = 138, 24.5%).

CONCLUSION

A large number of SRs about COVID-19 have been conducted, and many of the assessed records were poorly reported and would be difficult to replicate. Besides, collected data points to an epidemic of redundant reviews on COVID-19.

摘要

目的

本研究旨在评估在国际前瞻性系统评价注册库(PROSPERO)中 COVID-19 相关系统评价(SR)不同设计的特征。

方法

采用 PROSPERO 数据库提出的策略在数据库中进行检索,仅考虑人类研究。检索的最后日期为 2020 年 4 月 27 日。查阅了所有记录的全文,并由一名研究人员提取数据,另一名研究人员进一步进行了双重检查。使用表格对记录特征进行描述性分析。

结果

我们纳入了 564 条记录,其中绝大多数为 SR(n=513,91%)。总体而言,我们发现报告质量较差,存在缺失或混淆的信息,因为 84%(n=474)的记录未报告将采用的完整检索,16%(n=90)未清楚报告将使用的数据库,49.1%(n=277)未报告主要结局的数量。大多数记录的主要关注点是临床、流行病学、并发症和实验室特征(n=173,30.7%)或 COVID-19 的治疗(n=138,24.5%)。

结论

针对 COVID-19 开展了大量的 SR,但许多评估记录的报告质量较差,难以复制。此外,收集的数据表明 COVID-19 存在大量冗余的综述。

相似文献

1
The mass production of systematic reviews about COVID-19: An analysis of PROSPERO records.大规模生产关于 COVID-19 的系统评价:PROSPERO 记录分析。
J Evid Based Med. 2021 Feb;14(1):56-64. doi: 10.1111/jebm.12426. Epub 2021 Feb 17.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Registration of systematic reviews in PROSPERO: 30,000 records and counting.PROSPERO 系统评价注册:30000 条记录,且仍在增加。
Syst Rev. 2018 Feb 20;7(1):32. doi: 10.1186/s13643-018-0699-4.
4
Characteristics of registered and published systematic reviews focusing on the prevention of COVID-19: a meta-research study.关注 COVID-19 预防的注册和已发表系统评价的特征:一项元研究。
BMJ Open. 2022 May 9;12(5):e060255. doi: 10.1136/bmjopen-2021-060255.
5
Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic.关于 COVID-19 大流行的学术出版物、预印本和注册临床试验的特征。
PLoS One. 2020 Oct 6;15(10):e0240123. doi: 10.1371/journal.pone.0240123. eCollection 2020.
6
Prevalence of depression during the SARS, MERS, and COVID-19 pandemics: A protocol for overview of systematic reviews.非典、中东呼吸综合征和新冠疫情期间抑郁症的患病率:系统评价概述方案
Medicine (Baltimore). 2020 Sep 18;99(38):e22235. doi: 10.1097/MD.0000000000022235.
7
Measures implemented in the school setting to contain the COVID-19 pandemic: a scoping review.学校为遏制新冠疫情而采取的措施:一项范围综述
Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD013812. doi: 10.1002/14651858.CD013812.
8
Evaluating characteristics of PROSPERO records as predictors of eventual publication of non-Cochrane systematic reviews: a meta-epidemiological study protocol.评价 PROSPERO 记录特征对非 Cochrane 系统评价最终发表的预测作用:一项meta 流行病学研究方案。
Syst Rev. 2018 Mar 9;7(1):43. doi: 10.1186/s13643-018-0709-6.
9
Characteristics of systematic reviews evaluating treatments for COVID-19 registered in PROSPERO.评价 COVID-19 治疗方法的系统评价的特征,这些评价已在 PROSPERO 中注册。
Epidemiol Infect. 2021 Jun 16;149:e146. doi: 10.1017/S0950268821001321.
10
Epidemiology, methodological quality, and reporting characteristics of systematic reviews and meta-analyses on coronavirus disease 2019: A cross-sectional study.2019 年冠状病毒病的系统评价和荟萃分析的流行病学、方法学质量和报告特征:一项横断面研究。
Medicine (Baltimore). 2021 Nov 24;100(47):e27950. doi: 10.1097/MD.0000000000027950.

引用本文的文献

1
Exploring decision-makers' challenges and strategies when selecting multiple systematic reviews: insights for AI decision support tools in healthcare.探讨决策者在选择多个系统评价时所面临的挑战和策略:对医疗保健中 AI 决策支持工具的启示。
BMJ Open. 2024 Jul 5;14(7):e084124. doi: 10.1136/bmjopen-2024-084124.
2
The importance of meta-research in dentistry.牙科中荟萃研究的重要性。
Evid Based Dent. 2023 Sep;24(3):98-99. doi: 10.1038/s41432-023-00880-w.
3
Prevalence of soil-transmitted helminth infections in HIV patients: a systematic review and meta-analysis.HIV 患者土壤传播性蠕虫感染的流行率:系统评价和荟萃分析。
Sci Rep. 2023 Jul 8;13(1):11055. doi: 10.1038/s41598-023-38030-y.
4
Setting new research in the context of previous research: some options.将新研究置于先前研究的背景下:一些选择。
BMJ Evid Based Med. 2024 Jan 19;29(1):44-46. doi: 10.1136/bmjebm-2023-112300.
5
COVID-19 Public Health Measures and Patient and Public Involvement in Health and Social Care Research: An Umbrella Review.COVID-19 公共卫生措施与患者和公众在卫生和社会保健研究中的参与:伞式综述。
Int J Environ Res Public Health. 2023 Mar 10;20(6):4887. doi: 10.3390/ijerph20064887.
6
A suggested data structure for transparent and repeatable reporting of bibliographic searching.一种用于透明且可重复报告文献检索的建议数据结构。
Campbell Syst Rev. 2022 Nov 23;18(4):e1288. doi: 10.1002/cl2.1288. eCollection 2022 Dec.
7
Reporting quality of scoping reviews in dental public health.口腔公共卫生范围综述报告质量。
BMC Med Res Methodol. 2023 Feb 27;23(1):53. doi: 10.1186/s12874-023-01863-2.
8
Three out of four published systematic reviews on COVID-19 treatments were not registered and one-third of those registered were published: a meta-research study.四分之三已发表的关于 COVID-19 治疗方法的系统评价未注册,已注册的三分之一已发表:一项元研究。
J Clin Epidemiol. 2022 Dec;152:36-46. doi: 10.1016/j.jclinepi.2022.09.011. Epub 2022 Sep 27.
9
Characteristics of Living Systematic Review for COVID-19.新型冠状病毒肺炎(COVID-19)的活体系统评价特征
Clin Epidemiol. 2022 Aug 4;14:925-935. doi: 10.2147/CLEP.S367339. eCollection 2022.
10
Systematic reviews of convalescent plasma in COVID-19 continue to be poorly conducted and reported: a systematic review.COVID-19 恢复期血浆的系统评价继续存在方法学和报告质量差的问题:一项系统评价。
J Clin Epidemiol. 2022 Nov;151:53-64. doi: 10.1016/j.jclinepi.2022.07.005. Epub 2022 Aug 4.

本文引用的文献

1
PROTOCOL: When and how to replicate systematic reviews.方案:何时以及如何复制系统评价。
Campbell Syst Rev. 2020 May 28;16(2):e1087. doi: 10.1002/cl2.1087. eCollection 2020 Jun.
2
Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?瑞德西韦的现有证据及正在进行的临床试验:它会是治疗新冠病毒病的一个有前景的疗法吗?
Front Pharmacol. 2020 May 26;11:791. doi: 10.3389/fphar.2020.00791. eCollection 2020.
3
Dexamethasone for COVID-19? Not so fast.地塞米松治疗 COVID-19?先别急。
J Biol Regul Homeost Agents. 2020;34(3):1241-1243. doi: 10.23812/20-EDITORIAL_1-5.
4
Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.撤稿——羟氯喹或氯喹联合或不联合大环内酯类药物治疗新型冠状病毒肺炎:一项多国注册研究分析
Lancet. 2020 Jun 13;395(10240):1820. doi: 10.1016/S0140-6736(20)31324-6. Epub 2020 Jun 5.
5
"One more time": why replicating some syntheses of evidence relevant to COVID-19 makes sense.“再来一次”:为什么复制一些与 COVID-19 相关的证据综合是有意义的。
J Clin Epidemiol. 2020 Sep;125:179-182. doi: 10.1016/j.jclinepi.2020.05.024. Epub 2020 May 25.
6
RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.撤回:羟氯喹或氯喹联合或不联合大环内酯类药物治疗新型冠状病毒肺炎:一项多国注册分析
Lancet. 2020 May 22. doi: 10.1016/S0140-6736(20)31180-6.
7
A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?法匹拉韦的安全性综述——一种在新冠疫情中可能的治疗方法?
J Virus Erad. 2020 Apr 30;6(2):45-51. doi: 10.1016/S2055-6640(20)30016-9.
8
Waste in covid-19 research.新冠疫情研究中的浪费现象。
BMJ. 2020 May 12;369:m1847. doi: 10.1136/bmj.m1847.
9
Lessons from COVID-19 to future evidence synthesis efforts: first living search strategy and out of date scientific publishing and indexing industry (submitted).从 COVID-19 中吸取的教训,以促进未来的证据综合工作:第一个实时搜索策略和过时的科学出版和索引行业(已提交)。
J Clin Epidemiol. 2020 Jul;123:171-173. doi: 10.1016/j.jclinepi.2020.04.014. Epub 2020 Apr 27.
10
Methodological challenges in studying the COVID-19 pandemic crisis.研究新冠疫情危机中的方法学挑战。
J Clin Epidemiol. 2020 May;121:A5-A7. doi: 10.1016/j.jclinepi.2020.04.001.